ARIAD Pharma (ARIA) Shares Continue Lower as Feuerstein Piece Highlighted

Ariad Pharma (Nasdaq: ARIA) is reacting negatively to a week-old article on drug pricing issues posted by former Presidential candidate Bernie Sanders. Notably, biotech watcher Adam Feuerstein penned an article on the topic the prior day (Oct. 6th), specifically targeting Ariad in the piece.

With the report, Feuerstein noted that Ariad hiked the price of its leukemia drug Iclusig four times this year, with the latest being an 8 percent price hike.

Again, for the complete story, click here. Shares of Ariad are down nearly 13 percent.

You May Also Be Interested In

• Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
• Tesla (TSLA) continues to slide, breaks under $150
• Sage Therapeutics (SAGE) down 19% as its Parkinson's drug fails Phase 2 trials